Key result
The D389V mutation in MyBPC C2 decreased the melting temperature by 4 to 7 °C compared to wild type, while interactions with myosin and actin remained unchanged.
Why the study?
The recently discovered MYBPC3Δ25bp/D389V double mutation causes hyperdynamic features early in hypertrophic cardiomyopathy development, but its molecular pathomechanism remained uncharacterized.
The D389V mutation in MYBPC3 destabilizes the C2 domain thermodynamically and mechanically, providing a potential pathomechanism for hypertrophic cardiomyopathy in carriers.
Hypothesis-generating for thermodynamic destabilization as HCM pathomechanism in MYBPC3 D389V carriers; leaves open in vivo validation.
Cardiac myosin-binding protein C (MyBPC) is a thick-filament associated regulatory protein in the sarcomere. It regulates the sensitive contractile system of the myocardium by acting as a mechanical tether, sensitizing the thin filament or modulating myosin motor activity. Mutations in the MYBPC3 gene are a frequent cause for the development of hypertrophic cardiomyopathy, the most frequent cardiac disorder. Recently, the monoallelic double mutation MYBPC3Δ25bp/D389V has been discovered as a subset of the common MYBPC3Δ25bp variant in South Asia. MYBPC3Δ25bp/D389V carriers exhibit hyperdynamic features, which are considered an early finding for the development of hypertrophic cardiomyopathy. Using correlation-guided molecular dynamics simulations sampling, we show that the D389V mutation shifts the conformational distribution of the C2 domain of MyBPC. We further applied biochemical approaches to probe the effects of the D389V mutation on structure, thermostability and protein-protein interactions of MyBPC C2. The melting temperature (Tm) of MyBPC C2 D389V is decreased by 4 to 7 °C compared to wild type while the interaction of the C0-C2 domains with myosin and actin remains unchanged. Additionally, we utilized steered molecular dynamics (SMD) simulations to investigate the altered unfolding pathway of MyBPC C2 D389V. Based on our data, we propose a pathomechanism for the development of HCM in MYBPC3Δ25bp and MYBPC3Δ25bp/D389V carriers.
No takes yet. Share an insight, caveat, or question.
Schwäbe et al. (2021) studied Hypertrophic cardiomyopathy. MYBPC3Δ25bp/D389V mutation vs. Wild type was evaluated on Melting temperature (Tm) and protein-protein interactions. The D389V mutation in MyBPC C2 decreased the melting temperature by 4 to 7 °C compared to wild type, while interactions with myosin and actin remained unchanged.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: